Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 92

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 92
---
 Iris’s stockholders.

Risks Related to Ownership of ParentCo Common Stock Following the Business Combination

•

If the perceived benefits of the Business Combination do not meet the expectations of investors or securities analysts, the market price of ParentCo’s securities or, following the Business Combination, Liminatus’s securities, may decline.

•

Liminatus will be an emerging growth company, and it cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make its shares less attractive to investors.

Risks Related to Redemptions

•

If Iris’s stockholders fail to properly request redemption rights, they will not be entitled to redeem their shares for a pro rata portion of the Trust Account.

•

Iris’s public stockholders, together with any persons with whom they are acting as a “group”, will be restricted from seeking redemption rights with respect to more than 15% of public shares.

•

There is no guarantee that a public stockholder’s decision whether to redeem shares for a pro rata portion of the Trust Account will put such stockholder in a better future economic position.

Risks If the Adjournment Proposal Is Not Approved

•

If the adjournment proposal is not approved, and Iris is not otherwise authorized to consummate the Business Combination, the Business Combination will not be approved.

<div align='center'>22</div>

TABLE OF CONTENTS

SUMMARY HISTORICAL FINANCIAL INFORMATION OF IRIS The following table contains summary historical financial data as of and for the years ended December 31, 2023 and December 31, 2022 and as of and for the nine months ended September 30, 2024 and 2023. The results of operations for the nine months ended September 30, 2024 and 2023 are not necessarily indicative of the results of operations for the full year or any other interim period. The statement of operations data for the years ended December 31, 2023 and December 31, 2022, and the balance sheet data as of December 31, 2023 and December 31, 2022, are derived from the audited financial statements of the Company, which are included elsewhere in this proxy statement/prospectus. The statement of operations data for the nine months ended September 30, 2024 and September 30, 2023, and the balance sheet data as of September 30, 2024 are derived from the unaudited condensed financial statements of the Company, which are included elsewhere in this